COMP <GO>
DGX vs ABBV // ALTMAN Z-SCORE & DEBT/EQUITY
Quest Diagnostics Incorporated (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: DGX 7
— ABBV 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ABBV
LAST: $251.82 (-0.43%) • MKT CAP: $27.83B
balance-sheet
4.01
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
balance-sheet
5.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DGX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DGX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 33.20% | 70.20% | -37.00 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.30% | 29.00% | -18.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 16.3x | 33.3x | -17.00 | DGX | /valuation <GO> |
| Free Cash Flow Yield | 4.88% | 3.47% | +1.41 | DGX | /fcf-yield <GO> |
| Operating Margin | 14.10% | 24.60% | -10.50 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 9.00% | 6.90% | +2.10 | DGX | /net-margins <GO> |
| Revenue Growth (YoY) | 11.80% | 8.60% | +3.20 | DGX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.27% | 2.27% | -1.00 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 4.01 | 5.33 | -1.32 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | DGX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.40% | -0.50 | DGX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.3 | 72.8 | -4.45 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 1.15 | -0.14 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.1x | 113.1x | -87.00 | DGX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $27.83B | $513.86B | -$486.03B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DGX REV | ABBV REV | DGX GROSS % | ABBV GROSS % | DGX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $11.04B | $61.16B | 33.2% | 70.2% | $1.36B | $17.82B |
| FY 2024 | $9.87B | $56.33B | 32.9% | 70.0% | $909.0M | $17.83B |
| FY 2023 | $9.25B | $54.32B | 44.0% | 44.0% | $855.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DGX // BETA 1.01
ABBV // BETA 1.15